@d_stock07734 Avatar @d_stock07734 d_stock

d_stock posts on X about $nwbo, in the, dc, company the most. They currently have [---] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.

Engagements: [-----] #

Engagements Line Chart

Mentions: [--] #

Mentions Line Chart

Followers: [---] #

Followers Line Chart

CreatorRank: [-------] #

CreatorRank Line Chart

Social Influence

Social category influence stocks 35.21% finance 11.97% countries 1.41% currencies 1.41% social networks 0.7% technology brands 0.7% exchanges 0.7%

Social topic influence $nwbo #2, in the 14.08%, dc #2334, company 12.68%, the most 5.63%, paper #2365, $mrk #9, study #3412, imo #462, design 3.52%

Top accounts mentioned or mentioned by @mdendream @michael48826289 @metacollectiveg @mc17595091 @gonegoodguy @fatboychan74370 @peterdfellow @scottjenn63528 @timthomas0007 @investisco @andrewcaravello @kasperseninvest @patrickwalsh14 @alphavestcap @maxstradamus21 @johnwarner1970 @jaylourenco @itscarterhughes @kennethpar49290 @hspooner665

Top assets mentioned Merck & Co., Inc. (MRK) Kymera Therapeutics, Inc. (KYMR)

Top Social Posts

Top posts by engagements in the last [--] hours

"$NWBO Five DC vaccine trials (NCT05809752 NCT05378464 NCT03387553 NCT05325632 NCT05504707) conducted at Moffitt Cancer Center will be completed this year. It seems to me all of them produced amazing preliminary results. Imagine what would happen once keytruda and TLR agonists were combined with the DC vaccine A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) Study Start (Actual): 2023-08-22 Primary Completion (Estimated): 2026-03 Study Completion (Estimated): 2026-03 Enrollment (Estimated): [--] Study Type: Interventional Phase: Phase [--] Sponsor: H. Lee Moffitt Cancer Center and"
X Link 2026-02-12T22:42Z [---] followers, [----] engagements

"$NWBO There are over one thousand DC vaccine trials registered on How could only those trials that are connected to the 'symphony' institutions produce amazing results Those institutions conduct research on various maturation cocktails. But in terms of antigen uptake and cross-presentation by DCs only $NWBO owns the breakthrough. As the Company previously reported proteomic studies have demonstrated that a single tumor lysate sample contained tens of thousands of different peptides and out of this pool the dendritic cells selected processed and presented over [---] different peptides (tumor"
X Link 2026-02-10T06:13Z [---] followers, [----] engagements

"$NWBO The Column Group is really confident about the future of Eikon Therapeutics. https://www.thecolumngroup.com/tcg-team/ https://www.sec.gov/Archives/edgar/data/1861123/000119312526049209/xslSCHEDULE_13D_X01/primary_doc.xml $NWBO The Column Group used to be the largest shareholder of Immune Design which was developing TLR4 agonist. Now it is one of the main shareholder of Eikon Therapeutics. See something interesting https://t.co/3xGxd6ZkIC Phase 1/2 study of intratumoral G100 (TLR4 agonist) https://www.thecolumngroup.com/tcg-team/"
X Link 2026-02-13T16:20Z [---] followers, [----] engagements

"$NWBO TCG team has some interesting team members. Roger Perlmutter is currently a science partner. He was a science partner before as shown the following webpage dated in April [----]. Peter Svennilson as TCG founder used to serve as a board director for Immune Design which was developing TLR4 agonist (G100) and acquired by Merck with $300m. Have we seen LPS was used in manufacturing DC vaccines from the 'symphony' institutions Lipopolysaccharide (LPS) is the primary potent natural agonist of Toll-like receptor [--] (TLR4) triggering innate immune responses in Gram-negative bacteria. The trials on"
X Link 2026-02-15T05:11Z [---] followers, [----] engagements

"@MC17595091 There is only one DC vaccine that is working"
X Link 2026-02-15T18:04Z [---] followers, [--] engagements

"$NWBO It seems like Regeneron's Vidutolimod a TLR9 agonist produced some promising results in combination with keytruda on treating melanoma. Neoadjuvant Vidutolimod Plus Pembrolizumab Elicits Responses and Is Safe in Stage III Melanoma A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma https://clinicaltrials.gov/study/NCT04708418 https://www.onclive.com/view/neoadjuvant-vidutolimod-plus-pembrolizumab-elicits-responses-and-is-safe-in-stage-iii-melanoma"
X Link 2025-12-27T06:04Z [---] followers, [----] engagements

"$NWBO Kymera Therapeutics Inc. reported insider purchases by affiliated Baker Brothers funds in a public stock offering that closed on December [--] [----]. Investment fund [---] L.P. bought [------] shares of Kymera common stock and Baker Brothers Life Sciences L.P. bought [-------] shares each at a price to the public of $86.00 per share in an underwritten offering. Bros. Advisors Lp Baker purchased [-------] shares of Kodiak Sciences at an average price of $23 on Dec. [--] spending about $60.0M and raising their stake to [--------] shares (a 16.56% increase) valued at roughly $422M."
X Link 2025-12-28T00:35Z [---] followers, [----] engagements

"$NWBO SPORE project sponsored a trial on using the combination of TLR9 agonist (Vidutolimod Regeneron) with Keytruda to treat relapsed and refractory Lymphoma. Regeneron also conducted a trial using the combination to treat melanoma and the trial results were not bad. Should Regeneron and Merck be interested in combining Direct with Vidutolimod and Keytruda CMP-001 for Relapsed and Refractory Lymphoma Study Start (Actual): 2020-01-31 Primary Completion (Actual): 2024-08-23 Study Completion (Actual): 2025-04-08 Enrollment (Actual): [--] Collaborators: Checkmate Pharmaceuticals Merck Sharp &"
X Link 2026-01-08T06:45Z [---] followers, [----] engagements

"$NWBO The news on Revolution reminds me of what happened to Seagen. Merck in talks to buy biotech Revolution in up to $32 billion deal FT reports Merck Is in Advanced Talks to Buy Seagen for Roughly $40 Billion or More Pfizer Inc. completed the acquisition of Seagen Inc. from Baker/Tisch Investments L.P a funds managed by Baker Brothers Investments and others. https://www.marketscreener.com/quote/stock/PFIZER-INC-23365019/news/Pfizer-Inc-completed-the-acquisition-of-Seagen-Inc-from-Baker-Tisch-Investments-L-P-a-funds-mana-45571552/"
X Link 2026-01-09T15:49Z [---] followers, [----] engagements

"$NWBO Which company had the License and Supply Agreement with $NWBO for supplying TLR agonist Merck (TLR4 agonist) Eikon Therapeutics (TLR7/8 agonist) Regeneron (TLR9 agonist) Trisalus (TLR9 agonist) TLR3 agonist was combined with DCVAX in several trials. So Oncovir doesn't seem to be the one. Among all those TLR agonists only Eikons TLR agonist is something new. If Eikon is the one that struck the deal with $NWBO it would be great. https://investorshub.advfn.com/boards/read_msg.aspxmessage_id=177193840 https://investorshub.advfn.com/boards/read_msg.aspxmessage_id=177193840"
X Link 2026-01-21T16:04Z [---] followers, [----] engagements

"$NWBO How To Win Deals In A Competitive Market With Merck & Co. BD Exec Elizabeth Naldi-Jacob I suppose it is pretty easy for Merck to win deals because Merck has information asymmetry in terms of using immunotherapy to treat cancer. Did Merck tell Verona that its PDE3/4 dual inhibitor can overcome immunosuppression due to tumor-associated neutrophils I don't think Merck told Immune Design that its TLR4 agonist as potent maturation agents for immature dendritic cells (DCs) can be used to boost efficacy of DC vaccine. Seven and Eight BioPharmaceuticals didn't know the efficacy of Resiquimod"
X Link 2026-01-23T02:46Z [---] followers, [----] engagements

"$NWBO It is self-evident that BPs should know the trial results if they are among the collaborators or sponsors of the trial. Merck and Regeneron should know the importance of TLR9 agonist in cancer treatment. CMP-001 for Relapsed and Refractory Lymphoma Regeneron sees skin cancer potential beyond PD-1s with $250M Checkmate acquisition Regeneronplans to show there is more to skin cancer than PD-1 inhibitors through the $250 million acquisition of Checkmate Pharmaceuticals for the lead immuno-oncology asset vidutolimod. Vidutolimod is an agonist of a protein called toll-like receptor [--] that is"
X Link 2026-01-23T19:59Z [---] followers, [----] engagements

"$NWBO Indaptus Therapeutics Fireside chat - What are some of the key takeaways from the poster we presented at AACR Our poster not only confirmed the robust data from our preclinical animal studies but also demonstrated similar success with human immune cells in the lab. There has been a long-standing misconception that bacteria can only activate the innate side of the immune systemour results clearly show activation of the adaptive immune system as well. Excitingly our studies also revealed additive or synergistic effects when combined with the established cancer treatment Interleukin 2"
X Link 2026-01-26T22:57Z [---] followers, [----] engagements

"@Michael48826289 Who has been holding two seats on BeiGene board since [----] Was BeiGene trying to develop CSF1R inhibitor in collaboration with another company"
X Link 2026-01-27T06:16Z [---] followers, [--] engagements

"$NWBO Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy The FDA provided a Prescription Drug User Fee Act (PDUFA) goal action date of November [--] [----]. https://www.biospace.com/press-releases/summit-therapeutics-announces-u-s-fda-acceptance-of-biologics-license-application-bla-seeking-approval-for-ivonescimab-in-combination-with-chemotherapy-in-treatment-of-patients-with-egfrm-nsclc-post-tki-therapy"
X Link 2026-01-29T15:54Z [---] followers, [---] engagements

"@GoneGoodguy @maxstradamus21 It's going to be huge Not investment advice. I hope the longs hold this one as long as they can. Don't let those institutions take away shares easily"
X Link 2026-01-29T16:37Z [---] followers, [----] engagements

"Merck's acquisitions could have dual purposes. The good part is that all those drugs that Merck picked up through acquisitions are fungible. But there is only one technology that can organize various types of immune cells into a strike group to wipe out cancer cells. $NWBO is the owner of the technology Take IL-2 as an example. Baker Brothers also have investment in companies that are developing IL-2. https://twitter.com/i/web/status/2017008125186838763 https://twitter.com/i/web/status/2017008125186838763"
X Link 2026-01-29T22:53Z [---] followers, [----] engagements

"$NWBO Here is how Roger Perlmutter helped Merck acquired Immune Design for its TLR4 agonist. After the acquisition Merck published the trial results shelved TLR4 agonist program and let go all Immune Design researchers. Perlmutter met with Immune Design CEO Carlos Paya M.D. Ph.D. during a scientific conference to further discuss a potential licensing transaction. During that meeting the subject of an acquisition came up though Perlmutter did not specify a price according to the filing. Payas response Immune Design was not for saleespecially within the range of its then-current trading price."
X Link 2026-01-29T23:44Z [---] followers, [----] engagements

"$NWBO At the 13thNeuro-Oncology Brain Tumor Symposium held today Dr. Stephen Bagley gave a presentation. Recent and Ongoing Immunotherapy Clinical Trials for GBM Response Assessment in Long-Term Glioblastoma Survivors Using a Multiparametric MRI-Based Prediction Model https://www.med.upenn.edu/brain2026/assets/user-content/13th-brain-tumor-symposium-syllabus-2026-duplicate-duplicate-duplicate-duplicate.pdf https://www.mdpi.com/2076-3425/15/2/146 https://www.med.upenn.edu/brain2026/assets/user-content/13th-brain-tumor-symposium-syllabus-2026-duplicate-duplicate-duplicate-duplicate.pdf"
X Link 2026-01-30T21:23Z [---] followers, [----] engagements

"@TimThomas0007 @MDendream Let guess. You have been averaging down ever since"
X Link 2026-02-01T01:04Z [---] followers, [--] engagements

"$NWBO alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use https://patents.google.com/patent/US7972847B2/en https://pubmed.ncbi.nlm.nih.gov/15342370/ https://patents.google.com/patent/US7972847B2/en https://pubmed.ncbi.nlm.nih.gov/15342370/ $NWBO The significance of the BBC news on the trial which is about using tolerogenic DC vaccine to treat RA is extraordinary. There are different ways to maturate DCs depending on the"
X Link 2026-02-01T20:07Z [---] followers, [----] engagements

"$NWBO Eikon Therapeutics will be listed tomorrow and Merck is going to own 10% of the company. The true potential of its lead product EIK1001 a TLR7/8 agonist can be fully tapped only in combination with DCVax both L and Direct. Is EIK1001 among the three TLR agonists Dr. Bosch mentioned in his NYAS presentation We will know the answer soon. https://twitter.com/i/web/status/2018350992438259795 https://twitter.com/i/web/status/2018350992438259795"
X Link 2026-02-02T15:49Z [---] followers, [----] engagements

"$NWBO Merck is going to have sales and earnings call tomorrow. It strikes me that Merck's main theme last year was that Merck had [--] new growth drivers all of which had blockbuster potential. I was wondering what Merck will say tomorrow. Take a look at the ovarian cancer trial that LP mentioned at ASM. According to LP the trial produced 'quite strikingly encouraging' results. But the trial included nothing from Merck. Instead Pfizer's Prevnar vaccine was combined with DCVax-L. There are also several other DC vaccine trials which had Pfizer's Prevnar. I have no doubt that Merck's [--] new growth"
X Link 2026-02-02T22:16Z [---] followers, [----] engagements

"$NWBO Merck still has full confidence in its [--] new growth drivers and it specifically mentioned that ten of [--] new growth drivers could be substantially clinically derisked over the next two years. What could be the ten substantially clinically derisked new growth drivers Let me guess. TLR4 agonist IL-2 PCSK9 inhibitor CSF1R inhibitor TLR7/8 agonist Dual PDE4/5 inhibitor PCV21 Winrevair LSD1 inhibitor Sting agonist Does Merck need to combine at least ten of these new growth drivers with something that can truly differentiate in the next two years Today our business is anchored by an"
X Link 2026-02-03T17:30Z [---] followers, [----] engagements

"$NWBO The Pfizer guy was totally amazed by the results from DC vaccine trials on GBM breast cancer and melanoma. He probably didn't see the results from the DC vaccine trials on ovarian cancer. Otherwise he could have been amazed even more. LP mentioned that the collaboration trial on ovarian cancer between $NWBO and Penn delivered 'quite strikingly encouraging ' results. The trial had DCVax-L in combination with Roche's Bevacizumab (Avastin) Pfizer's Prevnar and cyclophosphamide. There are no publications on the trial. But we can take a reasonable guess on how strikingly encouraging the"
X Link 2026-02-05T15:51Z [---] followers, [----] engagements

"$NWBO Dr. Keith Knutson from Mayo Clinic also attended the conference organized by Cancer Vaccine Coalition. I assume by now Arun Balakumaran may have read some publications by Keith Knutson and other researchers at Mayo Clinic. Mayo once conducted a trial on advanced ovarian cancer by using DCs pulsed with peptides derived from FRalpha family antigens which can induce long-lived plastic effector memory cells called Th17 cells vital for long-term immune memory. That's why 40% of patients had OS over [--] years. Mayo is currently conducting another trial on advanced ovarian cancer using the same"
X Link 2026-02-05T17:57Z [---] followers, [----] engagements

"$NWBO Can the longs sense it The conference indicates that the 'symphony' is real All those prestigious research institutions play with different maturation cocktails to equip DCs with different properties and they also try to feed DCs with different peptides derived from different tumor antigens. In the end DCs need to fully digest and present whatever is fed to them and NWBO's 'Coca-Cola formula' is the key on this regard. https://x.com/StevenBremMD/status/1962268043028918637s=20"
X Link 2026-02-05T18:07Z [---] followers, [----] engagements

"@MDendream @JohnWarner1970 @JayLourenco @metacollectiveG Here is a question for distraction. When Kevin Duffy ends exile which company will he return Merck Eikon or NWBO"
X Link 2026-02-05T20:46Z [---] followers, [---] engagements

"$NWBO In [----] Merck spent $300m acquiring Immune Design for its lead product G100 which is TLR4 agonist. Roger Perlmutter convinced a significant stockholder of Immune Design to sell the company to Merck after Immune Design's CEO said no to him at first. It seems like the significant shareholder was the Column Group. The really interesting part is that Column Group is a significant shareholder of Eikon Therapeutics and has one seat on its board Perlmutter met with Immune Design CEO Carlos Paya M.D. Ph.D. during a scientific conference to further discuss a potential licensing transaction."
X Link 2026-02-06T04:54Z [---] followers, [---] engagements

"@FatboyChan74370 To sell a biotech company you have to have a rough idea about its potential and then put a price tag. Can Goodguybill put a price on this treatment first Now read again about the following part from ASM"
X Link 2026-02-06T04:59Z [---] followers, [---] engagements

"IMO BNTX as a company which has only 15% institutional ownership is basically all in the partnership with UK. Did $NWBO have a collaboration trial with Merck on colorectal cancer which was conducted at University Medical Center (UMC) of the Johannes Gutenberg University Mainz in Germany The trial was conducted between [----] and [----] according to the webpage. Did BNTX start the trial on BNT111 developed through FixVac platform in [----] But BNT111 didn't work. The interesting part is that the CEO of BNTX Ugur Sahin has been working at University Medical Center (UMC) of the Johannes Gutenberg"
X Link 2026-02-06T17:46Z [---] followers, [---] engagements

"$NWBO For all those DC vaccine trials that produced amazing results monocytes had to be collected first and later were differentiated into immuature DCs. Monocytes are adherent cells which means they can be like barnacles sticking to vessel wall. Zeon's device could be used to collect monocytes efficiently by adjusting the critical diameter of microarrays to match the diameter of monocytes. By now the longs may sense that LP likes running several separate projects in parallel. Convergence moment will come right after the approval Bioreactor on a chip: a microfluidic device for closed"
X Link 2026-02-06T20:03Z [---] followers, [----] engagements

"$NWBO I suppose those former Merck executives knew the intense anti-tumor immune response triggered by the combination of DCVax-L with Poly-ICLC and keytruda from the combo trial before they joined Eikon Therapeutics the so-called Merck [---]. EGFR is one tumor antigen highly overexpressed in GBM cancer cells. Take a look at the significant gene expression changes of EGFR in pre- vs. post-treatment in the case of DCVax-L in combination with TLR agonists. Again resiquimod 0.2% gel which had effective concentration of 0.2% TLR7/8 agonist was applied to ATL-DC injection site. I have no doubt those"
X Link 2026-02-06T21:02Z [---] followers, [----] engagements

"$NWBO Dr. Samir Khleif is on the SAB of $NWBO and has been funded by Merck. He also published paper on PARP inhibition and Eikon Therapeutics has two PARP1 inhibitors in phase [--] trials"
X Link 2026-02-06T23:01Z [---] followers, [----] engagements

"$NWBO Never saw a job posting from Merck in which denderitic cell was explicitly mentioned before. This is the first time that the word 'dendritic cell' was mentioned in a job posting. Associate Scientist Postdoctoral Fellow - Vaccinology Preferred Qualifications (Not Required) Expertise in B cell responses to vaccination or infection Experience with dendritic cell co-culture systems involving B and/or T cells Familiarity with antigen presentation assays Experience working with BSL-2 level viral pathogens Knowledge of B cell receptor (BCR) repertoire sequencing and analysis Experience with"
X Link 2026-02-07T05:47Z [---] followers, [----] engagements

"@PeterDFellow It's a postdoc position. HR might forget to desensitize this one. If we check linkedin we can Merck has hired researchers with backgrounds on dendritic cells"
X Link 2026-02-07T13:28Z [---] followers, [---] engagements

"$NWBO Kenneth C. Frazier to Retire as Merck CEO; Board Elects Robert M. Davis as Successor; Frazier to Continue as Executive Chairman So Mr. Frazier as the former chairman and CEO of Merck must be involved in making decisions on the massive construction of vaccine manufacturing facilities at Merck West Point Campus. Facilities including PCV21 and the Winterfell project. Now he is the board member of Eikon Therapeutics which has systemic administration version of TLR7/8 agonist (EIK1001). One figure is worth thousands of words. Take a look at the figure that Eikon Therapeutics included in its"
X Link 2026-02-07T18:33Z [---] followers, [----] engagements

"@FatboyChan74370 @PeterDFellow Negative. Had she received the check we should have seen something SEC filing. By a big check I mean upfront payment. BO is never on my radar"
X Link 2026-02-08T03:33Z [---] followers, [--] engagements

"My understanding is that Merck keeps secret anything possibly connected to DCVAX-L. Have we seen Merck released any PR about those vaccine manufacturing facilities at West Point Campus Merck also desensitizes job postings related to dendritic cells. Just my understanding though. Here is the PR about $1b facility at DE. https://www.merck.com/news/merck-breaks-ground-on-new-1-billion-biologics-center-of-excellence-in-wilmington-delaware/ https://www.merck.com/news/merck-breaks-ground-on-new-1-billion-biologics-center-of-excellence-in-wilmington-delaware/"
X Link 2026-02-08T05:45Z [---] followers, [--] engagements

"$NWBO Those researchers who left academia for Merck must be eager to embrace something exciting. It is something related to DC vaccine Juraj Adamik Principal Scientist Merck Full-time Sep [----] - Present [--] yr [--] mos Paul V. Munson Senior Scientist Cellular Immunology Merck Full-time Dec [----] - Present [--] yr [--] mos Lisa Butterfield Distinguished Scientist Merck Full-time Mar [----] - Present [--] yrs Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients https://www.nature.com/articles/s41467-023-42881-4"
X Link 2026-02-08T20:57Z [---] followers, [----] engagements

"$NWBO In terms of DC vaccine it is a small world. Everybody knows everybody"
X Link 2026-02-08T21:17Z [---] followers, [----] engagements

"I hope you will also enjoy reading the following. Did Dave Innes say that the significance of Bosch's NYAS presentation was neglected I can see big money from a couple of BPs. Merck has several TLR agonists. Amgen has Actimmune (Interferon Gamma-1b). Interferon- Added During Bacillus Calmette-Guerin Induced Dendritic Cell Maturation Stimulates Potent Th1 Immune Responses https://pmc.ncbi.nlm.nih.gov/articles/PMC239912/ https://pmc.ncbi.nlm.nih.gov/articles/PMC239912/"
X Link 2026-02-09T02:12Z [---] followers, [---] engagements

"$NWBO It is good to see that Merck still maintain its confidence in its [--] new growth drivers all of which have blockbuster potential. Let's see how long Merck can maintain the confidence. I would say this year is probably the most critical year for Merck. Elsewhere the company maintains that almost all of its more than [--] new growth drivers hold blockbuster potential with a more than $25 billion opportunity in oncology $20 billion in the cardiometabolic area and $15 billion in infectious diseases."
X Link 2026-02-09T15:40Z [---] followers, [----] engagements

"@Investisco @andrewcaravello I assume in treating Alzheimer's combination is also the way. ANVS drug can disrupt the formation of those bad proteins upstream and activated t-cells can clean up them that cover neurons. But Alzheimer's is something for the future for $NWBO"
X Link 2026-02-09T16:16Z [---] followers, [---] engagements

"$NWBO Really like the picture. Will Merck have deals with Zeon about new vials https://zeonsmi.com/industries/pharmaceuticals/ 🏰❄ $MRK Winterfell Booster-Class Architecture Why Combinatorial $NWBO #DCVax Booster Classes Require #Lyophilization and Make Personalization Possible at Scale The system requires lyophilization for one operational reason: it is not built around a single adjuvant. It is built https://t.co/KP8syOjI5J https://zeonsmi.com/industries/pharmaceuticals/ 🏰❄ $MRK Winterfell Booster-Class Architecture Why Combinatorial $NWBO #DCVax Booster Classes Require #Lyophilization and"
X Link 2026-02-09T18:13Z [---] followers, [----] engagements

"$NWBO Merck has two collaboration trials with Immutep on APC activating soluble LAG-3 protein which can directly activate antigen-presenting cells or APCs (e.g. dendritic cells monocytes) via the MHC Class II pathway Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) About Eftilagimod Alfa (Efti) Efti is a novel immunotherapy that directly activates antigen-presenting cells or APCs (e.g. dendritic cells monocytes) via"
X Link 2026-02-09T19:01Z [---] followers, [----] engagements

"$NWBO Why did Roger Perlmutter's Eikon Therapeutics run trials on tough targets (advanced solid tumors) The combination of checking point inhibitors with TLR7/8 agonist or PARP1 inhibitor is not going to work on advanced solid tumors. We can see that two trials were marked as completed after enrolling one patient each. BeOne being the largest holding of Baker Brothers has been conducting a series of trials on PARP1 inhibitors over the past many years including the combination of PARP1 inhibitor with PD-1 inhibitor on advanced solid tumors. The results were mediocre. The only reasonable"
X Link 2026-02-09T22:53Z [---] followers, [----] engagements

"Right it is not about t-cells only. DCVAX-L can organize a strike groups consisting various immune cells including stem-cell like memory t cells essential for long-term immune memory. What I don't agree with you is the word 'compelling'. Hundreds of patients received DCVax-L through compassionate use program. Patients with fifteen types of solid tumors received the drug. 'most them blockbuster drugs' according to Les. So I think the treatment has passed the compelling stage. https://www.nature.com/articles/s41467-024-48073-y https://www.nature.com/articles/s41467-024-48073-y"
X Link 2026-02-10T15:56Z [---] followers, [--] engagements

"$NWBO Niktimvo a CSF1R inhibitor brought Incyte and Syndax a revenue of $156m in the year of [----] while the revenue of Daiichi's Turalio another CSF1R inhibitor went down last year. Again CSF1R inhibitor can deplete tumor-associated macrophages (TAMs) from tumor microenvironment by preventing monocyte14 from differentiating into TAMs. As Dr. Liau mentioned based on the results from the combo trial TAMs is the major hurdle for the improvement of the efficacy of DCVax-L. So intense anti-tumor immune response was observed first from the combo trial. Then Incyte decided to develop CSF1R inhibitor"
X Link 2026-02-10T17:53Z [---] followers, [----] engagements

"$NWBO Merck and Daiichi once conducted a collaboration trial on advanced solid tumors using the combination of Keytruda with PLX3397 (CSF1R inhibitor). A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors The trial was terminated after enrolling [--] patients because of lack of efficacy. This two inhibitors only work when massive t-cell infiltration into tumor site happens in the first place and tumor-associated macrophages follow which should be known to Dr. Antoni Ribas a colleague of Dr. Liau's who was involved in the trial along with"
X Link 2026-02-10T21:39Z [---] followers, [----] engagements

"$NWBO Why did Merck need TLR4 agonist Lipopolysaccharide (LPS) is a potent primary agonist for Toll-like receptor [--] (TLR4) triggering innate immune responses inflammation and cytokine production by acting as a Pathogen-Associated Molecular Pattern (PAMP). Here is the description about manufacturing DC vaccine developed by Pawel Kalinski. LPS was included. BTW IFN-gamma can be Actimmune. Any long who has interest in DC vaccines developed by the 'symphony' institutions should check out to see if LPS has to be used. What about the Direct"
X Link 2026-02-11T03:10Z [---] followers, [----] engagements

"$NWBO NCI conducted a trial on rare tumors of over [--] types using PD1 inhibitor and CTLA-4 inhibitor. How could NCI not include GBM Did NCI miss GBM on purpose Had NCI tried neoadjuvant two inhibitors NCI could have some good results by now. Nivolumab and Ipilimumab in Treating Patients With Rare Tumors https://clinicaltrials.gov/study/NCT02834013 🚨HOLY COW: RFK Jr says NIH corruption is why there isnt a cure for Alzheimers. "We should have the cure for Alzheimers today. We dont have it PURELY because of corruption at NIH. And we are going to have it quickly." Do you support RFK Jr. Follow:"
X Link 2026-02-12T18:10Z [---] followers, [----] engagements

"Does CD45RO fall into the subset of stem-cell like memory t-cell IL-7 can significantly expand stem-cell like memory t-cells. But I suppose newly expanded memory t-cells need to be presented with the target (tumor-antigens) so that they can pinpoint cancer cells and wipe them out. That's why the combination of IL-7 with PD1 inhibitor in treating cancer lacks of efficacy because t-cells have no target information. That's also the reason that the combination of IL-7 with DC vaccine in treating tough rare pediatric sarcomas produced amazing results. A Phase II Open-Label Randomized Clinical"
X Link 2026-02-13T17:25Z [---] followers, [--] engagements

"Fujifilm Bio has plenty interesting stuff PRIME-XV Dendritic Cell Maturation CDM Chemically-defined animal component-free medium for dendritic cell culture A Versatile and Reliable Basal Medium for MSC Expansion: PRIME-XV MSC Basal XSFM with Human Platelet Lysate https://fujifilmbiosciences.fujifilm.com/media/fujifilm/Resources/0/2/023786-msc-basal-xsfm-scientific-poster.pdf https://fujifilmbiosciences.fujifilm.com/media/fujifilm/Resources/0/0/003578_prime-xv_dendritic_cell_maturation_cdm.pdf"
X Link 2026-02-13T18:02Z [---] followers, [--] engagements

"@kaspersenInvest @KennethPar49290 @scott_jenn63528 I would love BO. But it won't happen. Six immune boosters that can supercharge DCs may come from at least two BPs"
X Link 2026-02-14T17:47Z [---] followers, [--] engagements

"@patrickwalsh14 @kaspersenInvest @scott_jenn63528 Exactly All these BPs need to compete with each other so that they can motivated and act fast and in the end cancer patients can get the maximum benefit"
X Link 2026-02-14T17:49Z [---] followers, [--] engagements

"$NWBO In [----] Actimmune (Interferon gamma 1b) along with other ultra-rare products brought Amgen revenue in the amount of $658m. Actimmune was one of the products formerly owned by Horizon Therapeutics which was acquired by Amgen with $28b in cash. I suppose Amgen can easily make its Actimmune a blockbuster new growth driver by choosing Actimmune to work as immune booster for the Direct. Toll-Like Receptor Ligands and Interferon- Synergize for Induction of Antitumor M1 Macrophages https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2017.01383/full"
X Link 2026-02-08T05:04Z [---] followers, [----] engagements

"$NWBO NCI once sponsored a trial on using DC vaccine to treat rare pediatric sarcomas. DCs were pulsed with tumor lysate acquired via percutaneous biopsy at enrollment. The results were truly amazing. There was supposed to be more trials which never happened. Let me guess why there were no more trials. If cancer were cured NCI would be out of business Therapy to Treat Ewing's Sarcoma Rhabdomyosarcoma or Neuroblastoma Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas"
X Link 2026-02-12T19:56Z [---] followers, [----] engagements

"@MDendream Will the people who own 35% of Incyte be interested in owning a certain percentage of $NWBO"
X Link 2026-02-11T18:55Z [---] followers, [----] engagements

"Merck can easily solve BCG shortage issue by working day and night. But Mecrk didn't. Instead Merck has been working like crazy to complete those vaccine manufacturing facilities at West Point Campus on which Merck hasn't released any PR yet. Amgen created a record in the history of the company in terms of completion speed constructing biologic manufacturing facility at New Albany. What stuff could possibly motivate the two so much It must be something really concerning their future https://twitter.com/i/web/status/2022741669981098155 https://twitter.com/i/web/status/2022741669981098155"
X Link 2026-02-14T18:36Z [---] followers, [--] engagements

"We can use Prometheus as an example. The market for UC and CD was $23b in [----]. Merck paid $11b in [----]. The solid tumor market in [----] is $209.6b from the internet. Now I suspect it should be $300b. The price tag should $150b at minimum since the market on antiviral and antibacterial fields and autoimmune diseases are not included and the potential loyalty from licensing neo-peptides found by the use of DCVax-L. Can any BP pay $150b The franchise is a clear signal that there is no BO"
X Link 2024-03-23T14:14Z [---] followers, [----] engagements

"Here is the part from NWBO's PR on the challenge of isolating adherent dendritic cells without damage. The special difficulty involved in developing the Flaskworks machine was that unlike other cell types the dendritic cells tightly adhere to the surface of the culture vessel (similar to barnacles). Extracting them from inside the culture vessel without damaging the cells or reducing the yield of doses was extremely challenging. Other cells (including T cells) are generally cultured suspended in liquid in a bag which makes it much easier to move them through processes. Many companies have"
X Link 2024-07-15T14:50Z [---] followers, [----] engagements

"Can you believe it $NWBO is a small company on OTC. But BPs like Merck and BMS were trying to have collaboration trials on some of the most difficult cancers GBM and colorectal cancer. This fact alone should intrigue people. Not to mention the amazing results we have seen now. I even speculate that the $74b acquisition of Celgene by BMS might be related to the fact that BMS was out of the combo trial on rGBM and the SPORE research project. Is it possible that Merck pushed BMS out through a bidding war Teresa Bitetti did join Takeda as President Global Oncology after the acquisition. According"
X Link 2025-01-16T20:59Z [---] followers, [----] engagements

"$NWBO George Coukos appointed director of new Ludwig Laboratory for Cell Therapy https://www.ludwigcancerresearch.org/news-releases/george-coukos-appointed-director-of-new-ludwig-laboratory-for-cell-therapy/trk=feed_main-feed-card_feed-article-content https://www.ludwigcancerresearch.org/news-releases/george-coukos-appointed-director-of-new-ludwig-laboratory-for-cell-therapy/trk=feed_main-feed-card_feed-article-content"
X Link 2026-02-06T06:55Z [---] followers, [---] engagements

"@Hspooner665 The UK medical system has the following as its priority. BNTX is even trying to develop its own DC vaccine. But one way or another $NWBO will have the approval. It's just the matter of time. https://www.biontech.com/int/en/home/pipeline-and-products/platforms/mrna-platforms.html https://www.gov.uk/government/news/major-agreement-to-deliver-new-cancer-vaccine-trials https://www.biontech.com/int/en/home/pipeline-and-products/platforms/mrna-platforms.html https://www.gov.uk/government/news/major-agreement-to-deliver-new-cancer-vaccine-trials"
X Link 2026-02-06T16:21Z [---] followers, [----] engagements

"Totally agree Hundreds of compassionate use patients received DCVax-L through the UK Specials program. I assume the number is only for those patients who agreed to let $NWBO collect their data. The real number could be bigger. Yet after over two years still no approval. There are no other reasonable explanations for the delay. https://twitter.com/i/web/status/2019815060927926276 https://twitter.com/i/web/status/2019815060927926276"
X Link 2026-02-06T16:46Z [---] followers, [----] engagements

"There is a company trying to develop DC vaccine to treat Alzheumer's by pulsing DCs with E22W mutant peptide. $NWBO's DC vaccine technology can pulse DCs with either tumor lysate or peptides derived from specific antigen. I see no problem that our technology can be used to treat Alzheimer's. Study in Subjects With Mild-to-Moderate Alzheimer's Dementia https://alzamend.com/pipeline/ https://clinicaltrials.gov/study/NCT05834296 https://alzamend.com/pipeline/ https://clinicaltrials.gov/study/NCT05834296"
X Link 2026-02-09T15:23Z [---] followers, [---] engagements

"It is weird isn't it Hundreds of patients received DCVax-L through the UK Specials Program by paying on their own. The data should be overwhelming. How many patients could be like the two case as shown in the $NWBO's ASCO presentation Politicians should not debate. They should bring those people in charge to testify on why the approval takes perversely long. https://twitter.com/i/web/status/2020957518802112788 https://twitter.com/i/web/status/2020957518802112788"
X Link 2026-02-09T20:26Z [---] followers, [----] engagements

"$NWBO [----] Dr Corey Cutler discloses: Stock/shareholder (self-managed) fees from Allogene Therapeutics Inc. Actinium Pharmaceuticals Inc. Bluebird bio Inc. Cue Biopharma Inc. Northwest Biotherapeutics Inc. and Verastem Inc. [----] Revisiting Timing and Decision Modeling for Allogeneic Hematopoietic Stem-Cell Transplantation in Myelodysplastic Syndromes Corey Cutler Stock and Other Ownership Interests: Bluebird Bio Verastem Northwest Biotherapeutics Actinium Pharmaceuticals 2Seventy Bio [----] Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across"
X Link 2026-02-10T23:01Z [---] followers, [----] engagements

"$NWBO The Column Group used to be the largest shareholder of Immune Design which was developing TLR4 agonist. Now it is one of the main shareholder of Eikon Therapeutics. See something interesting Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma Anatomy of a deal: How Merck closed Immune Design for $300M https://www.fiercebiotech.com/biotech/anatomy-a-deal-how-merck-closed-immune-design-for-300m https://pubmed.ncbi.nlm.nih.gov/34865586/ https://www.thecolumngroup.com/portfolio/ 🚨Insider Trade Alert🚨 10% Owner Column Group IV GP LP has"
X Link 2026-02-11T00:23Z [---] followers, [----] engagements

"$NWBO Dr. Liau mentioned that the immunosuppressive tumor-associated marcophages (green dots) is a major obstacle to clinical benefit. [---] Temporal influence of PD-1 blockade after vaccination on macrophage-driven CD8+ T cell exhaustion within the glioblastoma microenvironment Conclusions This study reveals that timing may impact how ATL-DC and aPD1 combined therapies can alter the immune landscape of GBM and highlights tumor-associated macrophages as a major obstacle to clinical benefit. Future strategies targeting these populations or blocking their immunosuppressive interactions with"
X Link 2026-02-11T19:34Z [---] followers, [----] engagements

"Does NWBO's DC vaccine technology only make DCs uptake and cross-present tumor antigens from autologous tumor lysate The answer is NO. NWBO's DC vaccine can also make autologous DCs pulse with allogeneic tumor lysate. The paper didn't mention about $NWBO. But the science tells me the technology used in the trial should be connected to the DC vaccine technology owned by $NWBO. Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma https://millcreekls.com/dendritic-cell-vaccine-2/"
X Link 2026-02-12T16:59Z [---] followers, [---] engagements

"$NWBO A beautiful post Thanks @andrewcaravello In Pennsylvania non-exempt employees must be paid [---] times their regular rate for all hours worked over [--] in a workweek mandated by both state law and the Federal Fair Labor Standards Act (FLSA). Employers cannot use "no overtime" policies to avoid paying for authorized or worked overtime. $NWBO #DCVax $MRK #Winterfell https://t.co/spspsGmGy7 $NWBO #DCVax $MRK #Winterfell https://t.co/spspsGmGy7"
X Link 2026-02-12T22:57Z [---] followers, [----] engagements

"$NWBO The results from DC vaccine trials conducted by Moffitt Cancer Center are already amazing. If these DC vaccine trials had nothing to do with $NWBO would the shorts promote these trials and use them to push $NWBO to the verge of bankruptcy Would the shorts spread the following news everywhere Would Merck spend billions acquiring the DC vaccine technology pushing $NWBO to bankruptcy and then collecting all $NWBO's IPs Again what would happen if DCs were supercharged by immune boosters as shown in Dr. Bosch's NYAS presentation"
X Link 2026-02-13T01:29Z [---] followers, [----] engagements

"$NWBO Has Merck invested $30m Eikon Therapeutics yet https://www.sec.gov/edgar/browse/CIK=1861123&owner=exclude https://www.ainvest.com/news/merck-invests-30mln-eikon-therapeutics-enters-multi-year-oncology-pact-guardant-health-2602/ https://www.sec.gov/edgar/browse/CIK=1861123&owner=exclude https://www.ainvest.com/news/merck-invests-30mln-eikon-therapeutics-enters-multi-year-oncology-pact-guardant-health-2602/"
X Link 2026-02-13T16:24Z [---] followers, [---] engagements

"@ProfSmithsonian @scott_jenn63528 Merck has to collect first all the synergistic or complementary treatments by paying as minimum as possible. To do this $NWBO has to be in low-profile. IMO"
X Link 2026-02-14T17:45Z [---] followers, [---] engagements

"$NWBO Moffitt Magnolia Ball Raises Millions To Benefit Cancer Research and Treatment Nearly 1000attendeesfilled the room atMoffitt Cancer Centers31st annual Magnolia Ballall sharing the samemission: to contribute to the prevention and cure of cancer. Over the past [--] years the Magnolia Ball has raised more than $50 million for innovative cancer research. Along with a live and silent auction and a special performance by award-winning reggae artist Ziggy Marley the crowd heard from patientDallas Carroll a young mother diagnosed withmetastatic breast cancer at the age of 29.Carroll credits a"
X Link 2026-02-14T22:40Z [---] followers, [----] engagements

"Sure can. Autoimmune diseases super bugs fungus infection infectious diseases and so one and so forth. Plus do mammals have dendritic cells IMO $NWBO's core technology is the platform that California Institute for Immunology and Immunotherapy is going to use to explore the possibilities that seem infinite at this point. https://www.calimmunology.org/ https://www.calimmunology.org/"
X Link 2026-02-15T18:03Z [---] followers, [---] engagements

"Well each of those 'symphony' institutions research on various maturation cocktails to make DCs produce more IL-12p40 and TNF-alpha. But they must use some of the core DC vaccine technologies from $NWBO. Here is the paper about loading DCs with antigens related to tumor blood vessel to treat advanced melanoma. I cannot see amazing results. In fact if we check the data from the Nature article about the combination of DCVax-L with TLR agonists we can see all those antigens if highly overexpressed in cancer cells can be taken care of within one month of the DC vaccination. My point is that Pawel"
X Link 2026-02-15T18:31Z [---] followers, [---] engagements

"@metacollectiveG Just three shots within [--] days no chemo no radiation no terrible side-effects and patients can live over nine years. It is beyond miracle"
X Link 2023-09-15T23:52Z [---] followers, [----] engagements

"@BIO99_BIO99 Not a good news for Regeneron which has big bet on chimeric antigen receptor (CAR) T-cell therapy. But it surely makes us love DCVax-L even more. Has DCVax-L bring to immune system anything artificially made Did NWBO use synthetic this or that or engineering this or that None"
X Link 2023-11-28T19:39Z [---] followers, [----] engagements

"The start of hiring frenzy from AZN at Gaithersburg Maryland. Senior Global Study Manager Cell Therapy Oncology R&D Early Clinical Executive Director Head of Virology and Vaccine Research Early V&I Associate Scientist - Bioscience Immunology Senior Scientist Translational Proteomics Global Mass Spectrometry Senior Scientist In Vivo Pharmacology Cell Therapy Associate Director Analytical Cell Therapy Global MS&T Senior Director Oncology Safety Science & Discovery Associate Director Study Leader Cell Therapy Senior Scientist Immuno-Oncology Matan Companies Signs [------] SF Full-Building Lease"
X Link 2024-03-02T02:52Z [---] followers, [----] engagements

"The case study may be about Owain James. The tumor is 14cm only half of it can be removed and three vaccines were made. But with the intense anti-tumor response the remaining half shrank into cyst under continual pounding of the immune system. I suspect that in his case the combination of DCVax-L + poly-iclc + keytruda was adopted"
X Link 2024-03-05T23:19Z [---] followers, [----] engagements

"In the latest NCI report Dr. Kimryn Rathmell mentioned about the progress in cancer Moonshot which is specifically about cell therapy for solid tumors. One significant advance is about overcoming t cell exhaustion. From the Nature Preprint on the clinical trial sponsored in part by NCI it seems like Dr. Liau found the way to overcome t cell exhaustion. https://classic.clinicaltrials.gov/ct2/show/NCT01204684 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543402/pdf/nihpp-rs3287211v1.pdf"
X Link 2024-03-15T22:22Z [---] followers, [----] engagements

"In the collaboration trial PR on colorectal cancer between Merck and NWBO the following was mentioned. After completing certain preparatory activities including obtaining regulatory approvals the Phase II trial will treat patients for up to [--] months with DCVax-L and the checkpoint inhibitor Pembrolizumab followed by long-term follow-up. The effects of this combination therapy will be monitored with magnetic resonance imaging (MRI) as well as liquid biopsy measures. DCVax is a platform technology that uses activated dendritic cells (DCs) and is designed to mobilize the immune system to attack"
X Link 2024-03-17T04:25Z [---] followers, [----] engagements

"Take a look what was said in this patent. "There is a third class of tumor antigens that has rarely been used in vaccines due to technical difficulties in identifying them (Sensi et al. 2006). This class consists of proteins with tumor-specific mutations that result in altered amino acid sequences. Such mutated proteins have the potential to: (a) uniquely mark a tumor (relative to non-tumor cells) for recognition and destruction by the immune system (Lennerz et al. 2005); (b) avoid central and sometimes peripheral T cell tolerance and thus be recognized by more effective high avidity T cells"
X Link 2024-03-20T05:02Z [---] followers, [----] engagements

"AZN bought Fusion for $2.4b. Fusion's therapy targets the most common tumor specific mutant called EFGRvIII. Dr. Liau Nature preprint analyzed the variation of over 19k genes before and after receiving DCVax-L + Poly-ICLC. EFGRvIII is just one of them. It is logic to conjecture that researchers can find other tumor specific mutants so that the therapy can have better precision in attacking cancer cells. https://fusionpharma.com/wp-content/uploads/2023/04/AACR-poster_EGFRvIII_2023_FINAL.pdf"
X Link 2024-03-21T02:13Z [---] followers, [----] engagements

"@metacollectiveG @JackNdreu @IrishMc67 It could be both BPs and big funds since NWBO doesn't fit BPs' business models and ruin the portfolio of the big funds. Now I suspect everyone has to kneel if they want to be knighted. They need DCVax-L for their own survival"
X Link 2024-04-04T04:47Z [---] followers, [----] engagements

"Here are the major players of PD-1 and PD-L1 inhibitors and the market size for PD-1 and PD-L1 inhibitors is about $40b in [----]. All these PD1/L1 inhibitors lack of efficacy for cold tumors which account for 80% of all solid tumors. DCVax-L can turn cold tumor into hot one so that these BPs can find a much larger market for their products. So $15B each can be a reasonable number. Merck & Co. Inc. Hoffmann-La Roche Ltd AstraZeneca Novartis AG Sanofi Lilly Bristol Myers Squibb (BMS)"
X Link 2024-04-07T04:27Z [---] followers, [----] engagements

"Can we expect the exciting data on rGBM now since data on prostate caner is out "Our T cell expansion and tumor infiltration story is supported by additional data coming out in the next few weeks." President and Chief Operating Officer Matthew Vandermast highlighted the key attributes of Hiltonol a synthetic dsRNA designed to activate the bodys defense mechanisms against viruses and tumors. Oncovirs clinical targets are solid tumors and infectious disease indications including HIV and COVID. We have especially exciting data developing around recurrent glioblastoma and prostate cancer."
X Link 2024-04-11T23:43Z [---] followers, [----] engagements

"Without doubt. In this video from last October Les Goldman mentioned that [---] patients received DCVax-L treatment. At the ASCO last June Dr. Bosch said [---] GBM patients were treated with DCVax-L. It seems like within three or four months two hundred patients had DCVax-L treatment. Those patients had to pay big amount of money out of their own pockets. The efficacy must be amazing. Otherwise it cannot explain why patients would be willing to try the treatment out of their own pockets. https://www.youtube.com/watchv=9vvklPyeC8M https://www.youtube.com/watchv=9vvklPyeC8M"
X Link 2024-04-16T06:17Z [---] followers, [----] engagements

"@metacollectiveG Greg Do we love this part that NWBO licensed the DC vaccine technology"
X Link 2024-05-08T18:50Z [---] followers, [----] engagements

"Note that NWBO licensed the DC vaccine technology. Competing interests Andres Salazar is the Founder CEO and Scientific Director for Oncovir which provided the TLR agonist (Poly-ICLC) used in the trial. Linda M. Liau is a member of the Scientific Advisory Board for Northwest Bioetherapeutics Inc which has licensed the DC vaccine technology. All others declare no competing interests"
X Link 2024-05-08T18:55Z [---] followers, [----] engagements

"The enemy is often one we cant see and sometimes the enemy is hiding in plain sight. Many dangers avoid detection until it is too late. Cancerous tumors are certainly one such enemy. Matthew Vandermast President and COO of Oncovir explains So when you have an immunologically cold tumor it means that the tumor has evaded your bodys base immune system. Cancer has immunologic evasions that allow it to grow unchecked within the body. And what youll see in cold tumors is an immunological desert there arent enough immune cells including T-cells available in those areas for your body to fight"
X Link 2024-05-08T20:08Z [---] followers, [----] engagements

"We have a drug master file with the FDA and we have been in front of many of the worlds tier [--] regulatory agencies including the European Union Countries including France and Switzerland in addition to Canada Japan Brazil and Thailand. Our product is going to be able to be used around the world. Our big push is to get funding so that we can support the development of Hiltonol with our partners and get commercialized in one therapeutic area. https://gritdaily.com/cancer-therapy-oncovirs-hiltonol/ https://gritdaily.com/cancer-therapy-oncovirs-hiltonol/"
X Link 2024-05-08T21:47Z [---] followers, [----] engagements

"Another paper on p3 trial which showed DCVax-L had the most significant efficacy for the most life-threatening subtype of GBM can be published anytime from now. One of the co-authors is Mark Gilbert Chief of NCI Neuro-Oncology Branch. https://x.com/NIHBrainTumor/status/1788554520764592355 https://x.com/NIHBrainTumor/status/1788554520764592355"
X Link 2024-05-13T00:59Z [---] followers, [----] engagements

"Among over five thousand abstracts submitted to ASCO [----] only four are related to dendritic cell vaccine. These are only about clinical trials. NWBO is light years ahead any potential competitors. Low-dose radiation as a preconditioning regimen for dendritic cell vaccines Immunological profiling of glioblastoma cellular composition to predict response to dendritic cell vaccination. Efficacy of intrathecal delivery of peptide-pulsed type [--] conventional dendritic cell vaccine for the treatment of breast cancer-associated leptomeningeal disease in preclinical models A first-in-human study to"
X Link 2024-05-19T23:09Z [---] followers, [----] engagements

"Naysayers keep saying that the collaboration trial on colorectal cancer between $NWBO and $MRK was cancelled and never happened. IMO the trial is real and most like the results must be great. Why The trial was still listed as one of research projects on the webpage of Johannes Gutenberg-Universitt Mainz in [----] the same year of the completion of the research project. More importantly based on the disclosure on the conflict of interest over the past ten years the PI of the trial professor Markus Moehler has been in close collaboration with Merck (MSD). There was no overlapping between him and"
X Link 2024-05-29T18:35Z [---] followers, [----] engagements

"Labcorp has technology for transcriptomic analysis and the company happens to account for 15% of SIO's portfolio. I can picture SIO will load a lot of NWBO shares through the open market. Sio Capital Management LLC reports 36.81% increase in ownership of LH / Labcorp Holdings Inc. On May [--] [----] - Sio Capital Management LLC filed a 13F-HR form disclosing ownership of [------] shares of Labcorp Holdings Inc. (US:LH) valued at $49350551 USD as of March [--] [----]. The entity filed a previous 13F-HR on February [--] [----] disclosing [------] shares of Labcorp Holdings Inc. This represents a change in"
X Link 2024-06-20T02:13Z [---] followers, [----] engagements

"NCI report from Dr. Kimryn Rathmell has plenty interesting words. "Ending cancer as we know it requires progress against cancers that have proven the most difficult to treat such as pancreatic cancer and glioblastoma as well as the rarest of cancers including certain pediatric tumors." "Treating Cancer and Improving Survivorship. Advances in precision medicine are making it increasingly possible to tailor treatment to a specific cancers unique traits. However many cancers remain for which there arent effective treatments that extend life. Even when promising treatments are found it is"
X Link 2024-06-21T03:33Z [---] followers, [----] engagements

"The following is a clinical trial run by Roswell Park Cancer Institute in collaboration with Moffitt Cancer Center and University of Comprehensive Cancer Center. The really interesting part about this trial is that in April [----] the funding was changed from NCI into the Department of Defense. The funding from DoD is categorized as Breakthrough Award - Funding Level [--] - Clinical Trial - Partnering PI Option Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer"
X Link 2024-06-22T19:13Z [---] followers, [----] engagements

"As shown in the latest update on the combo trial the trial cannot be blind to the investigator. Why Recall Dr.Liau said in her presentation that the anti-tumor immune response was so intense that the patient had to go through surgery to get inflammation tissue removed. Later the patient had to take RA drug to suppress immune response. It was not a singular event. Dr. Liau said there were a couple of others. Take a look again at how soon the intense anti-tumor immune response happened. It happened one week after the second shot NWBO's technology made a reality what Dr. Ralph Steinman dreamed"
X Link 2024-09-19T17:13Z [---] followers, [----] engagements

"Two clinical trials on dendritic cells have the updates recently with the dates fairly close to each other. One is using the technology licensed from NWBO. The other is run by Roswell Park with DoD funding. One interesting part is that about the same time the discussions and negotiations between NWBO and Roswell Park were started the funding for the dendritic trial run by Roswell was switched from NCI to DoD. It seems like this two trials are under close watch by some governmental sectors. Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From"
X Link 2024-09-23T21:32Z [---] followers, [----] engagements

"Roadmap to developing and delivering world-class research 2024-2026 https://www.kch.nhs.uk/wp-content/uploads/2024/09/Roadmap-to-developing-and-delivering-world-class-research-6.pdf https://www.kch.nhs.uk/wp-content/uploads/2024/09/Roadmap-to-developing-and-delivering-world-class-research-6.pdf"
X Link 2024-09-25T21:02Z [---] followers, [----] engagements

""Such information is consistent with recent data from other immune-responsive cancers such as melanoma in which the percentage of tumor-specific T cells recognizing known antigens was less than 1%." I keep reminding those bashers that $NWBO now should be worth tens of billions of dollars simply by being the supplier of neo-antigens which can be recognized by t cells"
X Link 2024-09-29T13:27Z [---] followers, [----] engagements

"Recall what Oncovir president talked about HIV in one of articles. Today the Lancet published a paper on the results from the trial on HIV vaccine development. Note that the vaccine is based on dendritic cell and poly-iclc is used as adjuvant. Again the $NWBO longs focus on the fact that DCVax-L can present hundreds of tumor-associated antigens to immune system. IMO pretty soon the longs will talk about DCVax-L can present immune system any antigens that result in diseases. President and Chief Operating Officer Matthew Vandermast highlighted the key attributes of Hiltonol a synthetic dsRNA"
X Link 2024-10-02T23:10Z [---] followers, [----] engagements

"@alphavestcap Fascinating paper The value of $NWBO is beyond measure https://ennodc.com/wp-content/uploads/2024/10/241002-EnnoDC-HIV-Phase-1-results-Press-Release-FINAL.pdf https://ennodc.com/wp-content/uploads/2024/10/241002-EnnoDC-HIV-Phase-1-results-Press-Release-FINAL.pdf"
X Link 2024-10-07T03:05Z [---] followers, [----] engagements

"Compassionate use program in the UK has been using the combination since January [----]. See the slides from Dr. Bosch. How many patents have been filed with Dr. Bosch listed among inventors A lot. Being a great scientist who is meticulous about all the details would Dr. Bosch put the slide on Case #2 before the one on Case #1 by mistake Well it could be speculation. But all those outcome measures in the current combo trial were never adopted before given its high profile would any parties in the combo trial have the guts to be so bold The answer is no. Then they must have verifiable data and"
X Link 2024-10-08T13:25Z [---] followers, [----] engagements

"Another exciting connection is about the clinical trial on three difficult-to-cure sarcomas treated with CYT107 in combination with DCs pulsed with tumor lysate plus keyhole limpet hemocyanin. Among [--] patients who had either metastatized or late recurrence cancer here is how tumor lysate was prepared. [--] had tumor tissue obtained via percutaneous core needle biopsy and/or fine needle aspiration and [--] through surgical resection. Five years later after patient enrollment over 30% enrolled patients were still cancer free at the time when the paper was published. Take a look at the figure on"
X Link 2024-11-16T06:56Z [---] followers, [----] engagements

"Dr. Ichim what you said is so true. Here is the paper about three pediatric sarcomas of cold type tumor treated with DC vaccine. $NWBO was not explicitly mentioned. But RevImmune was involved in the trial. All the patients had either metastatized or recurrent cancer. But after the treatment over 30% patients was still cancer free before the publication of the paper which was five years after the treatment. Note poly-iclc was not included. PD1 inhibitor was not. Neither FOXP3 inhibitor nor IDO inhibitor which overcome immunosuppression was added. I suspect the results would be even more"
X Link 2024-11-22T14:19Z [---] followers, [----] engagements

"Roswell was supposed to run a clinical trial on refractory colorectal cancer and for some reason the trial was withdrawn at the end of September. The reason for Withdrawn is prioritization of studies Reading the description of this trial makes me suspect the withdrawn of this trial must be related to the expansion of the trial as mentioned in the $NWBO latest 10Q. The phase II trial tests whether pembrolizumab and dendritic cell-based treatment works to shrink tumors in patients with colorectal cancer that does not respond to treatment (refractory). PRIMARY OBJECTIVE: I. To determine the"
X Link 2024-11-27T22:31Z [---] followers, [----] engagements

"Here is the expanded trial mentioned in the latest $NWBO 10Q. Four types of refractory cancers will be included in the trial: refractory lung breast bladder and melanoma. Refractory means unresponsive to checkpoint inhibitor drugs. These four types of cancers have one thing in common: Their immunosuppressive characteristics are myeloid-derived suppressor cells (MDSCs) dominant which brings the question: what is Celecoxib used in trial Celecoxib is COX-2 inhibitor which can overcome immunosuppression due to MDSCs. The even better part is that Interferon Alpha-2 Rintatolimod and Celecoxib are"
X Link 2024-11-28T01:40Z [---] followers, [----] engagements

"LP already selected one BP which can provide technology complementary to DCVax-L. IMO LP will run a tumor-agnostic combination trial covering several tough targets with immunosuppressive characteristic featured by tumor-associated macrophages. The trial will take several months. After the successful trial other BPs can front payments and strike franchise deals. BTW have you wondered why tumor shrinkage will be used as the outcome measure Should the whole tumor be surgically removed as much as possible If there is no tumor how could tumor shrinkage be adopted as outcome measure My"
X Link 2024-12-15T04:33Z [---] followers, [----] engagements

"But here is the good news. No one can bankrupt the company at this stage. In parallel with the combo trial Merck sponsored an expansion cohort on neoadjuvant PD1 inhibitor therapy for rGBM by enrolling [--] patients. The data of over [--] thousand genes collected after the therapy was in public domain. If you compare these numbers with the red color numbers from the ATL-DC + Poly-ICLC trial you can see the difference. It is not an apple-to-apple comparison. But Merck can have an apple-to-apple comparison. Methods To investigate this mechanism of immunotherapy resistance we performed single-cell"
X Link 2024-12-19T21:08Z [---] followers, [----] engagements

"The company has 'the best financing' in the past eight years. The interesting part is that YA II PN Ltd which provides the financing is also a big investor in Nascent Biotech which is developing monoclonal antibodies targeting various cancer types. The company just finished a phase [--] trial on using Pritumumab a IgG1 monoclonal antibody to treat rGBM patients with trial results being published three months ago. The more interesting part is about the two SAB member of Nascent. Dr. Santosh Kesari was directly involved in the p3 trial of DCVax-L and Dr. Ivan Babic published a bunch of papers"
X Link 2024-12-30T16:06Z [---] followers, [----] engagements

"Can you believe this dude claimed he has Ph.D. in biochemistry All those naysayers from medical field have stopped publishing attacking articles after the publication of the paper on the combination of DCVax-L with Poly-ICLC. I think they do realize that DCs primed by NWBO's technology can trigger massive and sustainable t cell infiltration into tumor site of the most difficult cancer on a magnitude never seen before in any other trials. But clueless minions still have no idea. https://www.nature.com/articles/s41467-024-48073-y https://www.nature.com/articles/s41467-024-48073-y"
X Link 2025-01-05T15:50Z [---] followers, [----] engagements

"Merck ran a mRNA trial on three tough targets: non-small-cell lung cancer pancreatic cancer and colorectal cancer. The trial results were posted two days ago. Seventy patients were enrolled. None of the patients completed the trial mainly because patients passed away. A couple of interesting points. The trial status was marked as COMPLETED in September [----] with Merck as sponsor and there was no collaborator. But this month the trial status was changed into TERMINATED out of business reasons and Moderna was included as the collaborator. There are no publications on this trial. I wonder if"
X Link 2025-01-31T05:15Z [---] followers, [----] engagements

"$NWBO already has the ultimate solution to cure cancer while others are still in a maze trying to figure out a way out of it. IMO. Those ADCs which are called bio-missiles need precise guiding system which is tumor-specific antigens. To find those antigens is not easy. But DCVax-L can help to identify those antigens very efficiently and easily. What if those antigens are inside cancer cells instead of on the surface cancer cells ADCs cannot touch antigens inside cancer cells only T cell receptor therapy can. What if there are no tumor-specific antigens"
X Link 2025-02-01T16:29Z [---] followers, [----] engagements

"@smith348572 Wow $100B I didn't know that. Holy Michael Had $MRK had the guts to acquire $NWBO ten years ago right after the poly-iclc trial was done by now $MRK could be the first trillion-dollar biotech company. LP really needs to charge $MRK huge late fee for not doing so years ago"
X Link 2025-02-04T17:51Z [---] followers, [----] engagements

"And the paper from the trial of CYT107 in combination with DC vaccine was referred in the publication. By now every NWBO long should know that there is only one company that can make dendritic cells swallow and digest tumor lysate and present hundreds of tumor-associated antigens to immune system which is the unique metric differentiating DC vaccine by $NWBO from other DC vaccines. Promising results were reported after CD25+ regulatory T-cell depletion of an autologous lymphocyte infusion product augmented with interleukin (IL)-7 where immune reconstitution correlated with an improved"
X Link 2025-02-20T00:01Z [---] followers, [----] engagements

"Let's see which companies might have all these inhibitors that can be complementary to DCVax-L. I really love the breath and depth & how expansive & all-inclusive $NWBO #DCVax combination patents with checkpoint inhibitors are. They include all checkpoint inhibitors & cover all solid tumor cancers & all blood or hematological cancers + these patents include the use of the https://t.co/0a1vfP7AlR I really love the breath and depth & how expansive & all-inclusive $NWBO #DCVax combination patents with checkpoint inhibitors are. They include all checkpoint inhibitors & cover all solid tumor"
X Link 2025-02-28T17:30Z [---] followers, [----] engagements

"Dr. Liau once ran a small trial on pediatric GBM. Among seven recruited patients three patients (#1 #4 #5) agreed to receive the DC vaccine. Two patients were alive at the time of the publication. I suppose if $NWBO had enough financial resources five or six years ago the company would have conducted another trial on pediatric GBM and more children's lives could have been saved. Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma Autologous Tumor Lysate-pulsed Dendritic Cell Immunotherapy for Pediatric Patients with Newly Diagnosed or Recurrent"
X Link 2025-04-02T15:26Z [---] followers, [----] engagements

"At this stage things are rather simple for $NWBO. Just follow the science: Can the portfolios of the two specific companies solve the puzzle with DCVax-L as the center https://beigene.com/science/pipeline/#solid-tumor-program https://incyte.com/what-we-do/pharmaceutical-portfolio#PortfolioDetails https://beigene.com/science/pipeline/#solid-tumor-program https://incyte.com/what-we-do/pharmaceutical-portfolio#PortfolioDetails"
X Link 2025-04-17T14:39Z [---] followers, [----] engagements

"Would you guys agree that $NWBO is a perfect target for Wallstreetbets at this stage [--] MMs have been trying for years to suffocate a company developing treatment for the most horrific type of cancer which is also the most life-threatening one for children. It's an OTC stock. So no calls and no halts. A simple 10k buy can trigger suspension from Stuttgart"
X Link 2025-04-18T14:40Z [---] followers, [---] engagements

"Here is the article about curing cancer written by Teresa Bitetti President Global Oncology Business Unit at Takeda. She used to work for BMY for [--] years before leaving in [----] as Senior VP on Oncology. I suppose she should be involved in doing DD on $NWBO and striking the deal of the collaboration trial on rGBM. Better Together: Our Aspiration to Cure Cancer Project 1: Active immunotherapy combined with checkpoint modulation for glioblastoma Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma"
X Link 2025-04-21T13:29Z [---] followers, [----] engagements

"I suppose every $NWBO long would agree that $NWBO certainly must have done the type of proteomic analysis like the one in the ASCO [----] presentation on fifteen types of solid tumors from the UK Specials Program. What we have seen today is not even the tip of a huge iceberg. But BPs who signed NDA should be able to see much more. https://nwbio.com/wp-content/uploads/NWBT_ASCO_slides_06032023_FINAL.pdf @MarieGrzenia $NWBO has data on fifteen types of solid tumors from Compassionate Use Program. GBM is the most difficult cancer given that there is blood-brain-barrier issue brain is immune"
X Link 2025-04-22T16:53Z [---] followers, [----] engagements

"Well said Any $NWBO longs who have doubt can simply take a look at the speed with which Merck ran the expansion cohort of neoadjuvant keytruda on treating rGBM. Also has Merck been consistently funding the combo trial I assume by now plenty rGBM patients far beyond [--] have received the treatment. Without doubt FDA should keep an eye on the progress and data of the combo trial. https://clinicaltrials.gov/study/NCT04201873 https://www.nature.com/articles/s41467-024-54326-7 https://clinicaltrials.gov/study/NCT02852655 $NWBO WEAK . HANDS should not be investing in NWBO . NWBO is a pioneering game"
X Link 2025-04-23T03:30Z [---] followers, [----] engagements

"Did LP once say: We could be the next Amgen IMO $NWBO could be bigger than Amgen. Take a look at Amgen's pipeline. $NWBO can take care of all the targets Amgen is shooting for. I suppose Amgen must have been working very hard to finally identify all those targets. $NWBO can give Amgen targets like these like candies. But it won't be free. BTW Amgen has two biosimilars for PD1 inhibitor. https://www.amgenpipeline.com/ https://www.amgenpipeline.com/"
X Link 2025-04-25T15:20Z [---] followers, [----] engagements

"Anyone who still has doubt about whether the technology that can pulse DCs with tumor lysate so that it can present hundreds of tumor-associated antigens has something to do with $NWBO should check out if those coauthors filed patents. Without doubt they would file patents if they made breakthrough of this magnitude. I suppose Michel Morre as the original founder of RevImmune formerly known as Cytheris should be allowed to use the patented technologies from $NWBO. Therapy to Treat Ewing's Sarcoma Rhabdomyosarcoma or Neuroblastoma Adjuvant Immunotherapy to Improve Outcome in High-Risk"
X Link 2025-04-25T15:55Z [---] followers, [----] engagements

"SESSION IV: Industry Blitz Next Generation Dendritic Cell Treatments to Improve Anti-Tumor Responses Marnix Bosch PhD Northwest Biotherapeutics Inc. $NWBO The last time Dr. Bosch spoke at a conference his proteomics analysis changed many minds in the industry. This may do it even more. Timing is the allShakespeare https://t.co/E9S1fs688N. $NWBO The last time Dr. Bosch spoke at a conference his proteomics analysis changed many minds in the industry. This may do it even more. Timing is the allShakespeare https://t.co/E9S1fs688N"
X Link 2025-04-29T17:29Z [---] followers, [----] engagements

"$NWBO is going to reveal to the world a totally revolutionary breakthrough in medicine. I suspect its value can be evaluated by the number of patients that $NWBO can treat. We all know that Merck is deeply involved in the combo trial. We also know that $NWBO has in-licensed technology from Roswell. Do we know that Merck is also sponsoring the DC vaccine trial by Roswell Note that out of $450m research payments Merck made to collaborators in [----] only three are related to clinical trials about dendritic cell. Here are the three trials. The first one is from UCLA and the results were published"
X Link 2025-05-01T17:51Z [---] followers, [----] engagements

"The results from the following trial are truly amazing. The patients were children and young adults aged [---] years who were diagnosed with relapsed/refractory and/or metastasizing high-risk solid tumors of [--] types. Two shots of DC vaccines were administered. The best responses recorded after the DC vaccination were: [--] patients had CR [--] had PR [--] had SD [--] had MR [--] had PD [--] patients died of disease and [--] others were censored at the date of evaluation. We observed repeated recurrences or progressions however with favorable overall survival. Three- and five-year overall survival was 80.8% and"
X Link 2025-05-04T06:07Z [---] followers, [----] engagements

"Thank you for working tirelessly to bring this very truth to $NWBO longs. I am certain they all get it. It couldn't be more obvious. The anti-tumor immune response from DC vaccine is directly related to the number of tumor antigens it can present. We can see from the paper that the efficacy is amazing. There is only one type of technology on this planet that can pulse DCs with tumor lysate and let them present hundreds of tumor antigens. $NWBO solely owns the technology and even UCLA has to get the license from $NWBO on this technology. You probably mentioned about the following before. It is"
X Link 2025-05-04T16:14Z [---] followers, [----] engagements

"After the publication of the results on the combo trial institutional investors will go through $NWBO's patents to find out if $NWBO filed different patents for different solid tumors. Once they realize that $NWBO's technology is for all solid tumors we may see a big firework show. The Question of All Questions: What Do [---] Billion Shares Actually Own in a Debt-Free $NWBO ⚖ Context Shift A company with [---] billion outstanding shares may seem bloated until the debt is fully cleared regulatory approval is imminent and that share base now owns: A The Question of All Questions: What Do 1.5"
X Link 2025-05-30T14:00Z [---] followers, [----] engagements

"Merck would have spent far more than $41b on acquisitions and collaborations had the results on either of two trials gone public. $NWBO already saved Merck lots of money. https://clinicaltrials.gov/study/NCT04201873 https://nwbio.com/nw-bio-announces-phase-ii-clinical-trial-program-combining-dcvax-l-and-pembrolizumab-keytruda-for-colorectal-cancer/ https://clinicaltrials.gov/study/NCT04201873 https://nwbio.com/nw-bio-announces-phase-ii-clinical-trial-program-combining-dcvax-l-and-pembrolizumab-keytruda-for-colorectal-cancer/"
X Link 2025-05-31T16:33Z [---] followers, [----] engagements

"FDAs Conditional Approval Plan Would Unleash Biotech Innovation Were going to be rolling out a new pathway for drugs which is a pathway based on a plausible mechanism This is exactly what $NWBO needs to make DCVax-L available for patients suffering from rare cancers. DCVax-L is working GBM and fifteen types of other solid tumors validated by the compassionate use cases in the UK Specials Program. Simply based on a plausible mechanism in combination with Keytruda CYT107 and CSF1R inhibitor DCVax-L will deliver amazing efficacy for over [--] rare cancers that the following trial failed to deliver"
X Link 2025-06-14T22:54Z [---] followers, [----] engagements

"I recall Dr. Ashkan mentioned that it only takes three shots of DC vaccines to reprogram immune system. We can see the amazing efficacy from the following trial that simple one dose of the combination of DCVax-L with TLR3/TLR7 brought. The expansion of IFR coverage to all solid tumors must be based on the solid data from the Specials program in which TLR3 should be included many years ago. Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy"
X Link 2025-07-01T17:28Z [---] followers, [----] engagements

"Merck also sponsored $270k for the DC trial conducted by Roswell with which $NWBO had in-license deal. Among top [--] BPs in the US only Merck is involved in clinical trials on using DC vaccines to treat cancers. And there are only two clinical trials: the combo trial conducted by UCLA and the one by Roswell. Is this definitive enough Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer https://clinicaltrials.gov/study/NCT04348747 https://clinicaltrials.gov/study/NCT04348747"
X Link 2025-07-01T19:13Z [---] followers, [----] engagements

"Look what was said on the webpage. It must have something to do with $NWBO. Otherwise $NWBO would have a tough competitor. Dendritic Cell Vaccine Allogeneic tumor lysates with classic GBM antigens and autologous dendritic cells capable of inducing an immune response. https://millcreekls.com/dendritic-cell-vaccine-2/ 📘 $NWBO $MRK: The Textbook and the Teacher & How #DCVAX-L Quietly Rewrote the Rules of Cancer Vaccines 📢 TLDR: Most people think DCVAX L is a personalized tumor vaccine but that is not exactly true. The real genius is that it trains your immune system using a prebuilt tumor"
X Link 2025-07-09T00:43Z [---] followers, [----] engagements

"Without doubt Yorkville's investment in $NWBO is long-term and strategic 🧠Strategic Convergence: Yorkville $NWBO Indaptus and Modular Immune Architecture 📡 TL;DR (22-25 min read): Yorkvilles dual financing of NWBO and $INDP reveals a deeper strategy: the rise of a programmable immunotherapy system. #DCVax DECOY20 and Eden form the core of an https://t.co/ILhNiPGLeM 🧠Strategic Convergence: Yorkville $NWBO Indaptus and Modular Immune Architecture 📡 TL;DR (22-25 min read): Yorkvilles dual financing of NWBO and $INDP reveals a deeper strategy: the rise of a programmable immunotherapy system."
X Link 2025-07-14T13:46Z [---] followers, [----] engagements

"The Evidence Across Mayos Trials: 1.NCT01957956 Newly Diagnosed GBM (Parney) Autologous DCs pulsed with pooled allogeneic GBM lysate (via Mill Creek Life Sciences). Delivered post-resection and radiation with temozolomide. Immune readouts included PD-L1/CTLA-4 upregulation and CD8+ infiltration. A direct match to the DCVax-L model. 2.NCT03360708 Recurrent GBM (Parney) Same platform applied to rGBM. Identical lysate source and maturation logic. Reproducible immunologic effects. Also used allogeneic pooled lysate. 3.NCT03325101 Melanoma (Block) Intratumoral DCs injected post-cryoablation"
X Link 2025-07-16T15:33Z [---] followers, [----] engagements

"10Q pointed out the previous trial in stage IV ovarian cancer delivered positive results. The combination adopted in the trial is: Prevnar + DCVax-L + Bevacizumab + Cytoxan. I suppose the results could be so stunning that the company chose to keep secret the results. How could the results not be good Prevnar can help stimulate immune system which means the expansion and proliferation of various immune cells. DCVax-L can present hundreds of tumor-associated peptides to immune cells. Bevacizumab a VEGF inhibitor from Roche can inhibit the growth of tumor blood vessel. Cytoxan as a chemo drug"
X Link 2025-08-17T22:36Z [---] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing